Inclusion Criteria

          -  Treatment-naïve, classic Hodgkin lymphoma (cHL) participants

               -  Participants enrolling in Part A of the study must have Ann Arbor Stage III or IV
                  disease

               -  Participants enrolling in Part B of the study must have Ann Arbor Stage I or II
                  cH: with bulky mediastinal disease, or Stage III or IV

               -  Participants enrolling in Part C of the study must have Ann Arbor Stage I or II
                  cHL without bulky disease

          -  Histologically confirmed cHL according to the current World Health Organization (WHO)
             Classification

          -  Bidimensional measurable disease as documented by PET/CT or CT imaging

          -  Age 12 years or older in the United States. For regions outside of the US,
             participants must 18 years or older.

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2

        Exclusion Criteria

          -  Nodular lymphocyte predominant HL

          -  History of another malignancy within 3 years of the first dose of study drug or any
             evidence of residual disease from a previously diagnosed malignancy. Exceptions are
             malignancies with a negligible risk or metastasis or death. Participants with
             nonmelanoma skin cancer, localized prostate cancer, or carcinoma in situ of any type
             are not excluded if they have undergone complete resection

          -  Prior immunosuppressive chemotherapy, therapeutic radiation, or any immunotherapy
             within 4 weeks of the first study drug dose

          -  Prior treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2, or anti-CTLA-4 antibody, or
             any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint
             pathways

          -  Active cerebral/meningeal disease related to the underlying malignancy

          -  Any active Grade 3 or higher viral, bacterial, or fungal infection within two weeks of
             the first dose of study drug (Grade 3 defined by the National Cancer Institute's
             Common Terminology Criteria for Adverse Events, NCI CTCAE Version 4.03)

          -  Current therapy with other systemic anti-neoplastic or investigational agents

          -  Planned consolidative radiotherapy (Parts B and C only)

          -  Active interstitial lung disease that is symptomatic or may interfere with the
             detection or management of suspected drug-related pulmonary toxicity (Parts B and C
             only)

          -  Grade 3 or higher pulmonary disease unrelated to underlying malignancy

          -  Documented history of idiopathic interstitial pneumonia or diffusing capacity of the
             lung for carbon monoxide <50% predicted

          -  History of a cerebral vascular event within 6 months of first dose of study drug

          -  Child-Pugh B or C hepatic impairment

          -  Grade 2 or higher peripheral sensory or motor neuropathy

          -  Participants with acute or chronic graft-versus-host-disease (GvHD) or receiving
             immunosuppressive therapy as treatment or as prophylaxis against GvHD

          -  Previous treatment with brentuximab vedotin

          -  Participants who are pregnant or breastfeeding

          -  Other serious condition that would impair the participant's ability to receive or
             tolerate the planned treatment and follow-up